Ligand Logo
Click here to bypass content and jump to navigation

Site Map

  • About Us
    • Overview
    • Message from CEO
    • Ligand Leadership
    • Board of Directors
    • Scientific Advisors
  • Pipeline
  • Promacta
  • Our Collaborations
    • Overview
    • Collaborations
      • GlaxoSmithKline
      • Merck
      • Bristol-Myers Squibb
      • Pfizer
      • Exelixis
      • Celgene
      • Chiva Pharmaceuticals
      • Baxter
      • Onyx
      • The Medicines Company
      • SAGE Therapeutics
    • Royalties
  • Licensing Opportunities
    • Overview
    • SARM
      • Diabetes Portfolio
    • Diabetes Portfolio
    • Captisol-Enabled Melphalan
    • EPO/GCSF
      • Captisol-Enabled Melphalan
    • Contact Business Development
  • Investors
    • Investor Overview
    • News & Events
    • Analyst Coverage
    • SEC Filings
    • Stock Information
    • Corporate Governance
    • Email Alerts
    • Contact Us
    • RSS Feeds
  • Captisol
Back to Top
Back to Top

Site 'Main' Navigation:

  • Home

Site 'Main' Navigation:

  • About Us
    • Overview
    • Message from CEO
    • Ligand Leadership
    • Board of Directors
    • Scientific Advisors
  • Pipeline
  • Promacta
  • Our Collaborations
    • Overview
    • Collaborations
    • Royalties
  • Licensing Opportunities
    • Overview
    • SARM
    • Diabetes Portfolio
    • Captisol-Enabled Melphalan
    • EPO/GCSF
    • Contact Business Development
  • Investors
    • Investor Overview
    • News & Events
    • Analyst Coverage
    • SEC Filings
    • Stock Information
    • Corporate Governance
    • Email Alerts
    • Contact Us
    • RSS Feeds
  • Captisol

Site 'Tertiary' Navigation:

  • Home
  • Register for Updates
  • Contact Us

Search The Site:

Enter Search Keywords and Submit

Follow Us On Twitter:

  • Twitter 

Current Stock Price:

NASDAQ: LGND $12.03

  • Terms of Use
  • Site Map